Temat: hormonotherapy - Katalog OPAC zbiorów

Skocz do pozycji: 1.

Tytuł:: Apalutamide treatment of locally advanced prostate cancer
Autorzy:: Palasik, Maria
Powiązania:: https://bibliotekanauki.pl/articles/22676859.pdf
Data publikacji:: 2023-03-31
Wydawca:: Medical Education
Tematy:: prostate cancer
castration resistance
hormonotherapy
apalutamide
Opis:: Prostate cancer is most commonly diagnosed cancer in men. The choice of treatment method depends on many factors: the patient’s age, other patient’s diseases, psychophysical status and expected survival time. Hormonotherapy plays very important role in patients with no possible radical treatment. New therapies apply in patients with castration-resistant metastatic prostate cancer. First registered drug in patients with biochemical progression without metastases is apalutamide.
Źródło:: OncoReview; 2023, 13, 1; 31-32
2450-6125
Pojawia się w:: OncoReview
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Skocz do pozycji: 2.

Tytuł:: The role of enzalutamide in the treatment of prostate cancer from the perspective of Polish oncologists
Autorzy:: Bal, Wiesław
Gajda, Maksymilian
Powiązania:: https://bibliotekanauki.pl/articles/2159010.pdf
Data publikacji:: 2022-06-30
Wydawca:: Medical Education
Tematy:: enzalutamide
prostate cancer
hormonotherapy
anti-androgen
second-generation an-
Opis:: For several years, prostate cancer has remained the most common malignancy in male patients in Poland. A large number of patients combined with rising costs of therapy translate into a significant socio-economic burden. In a clinical oncologist’s practice, we usually deal with patients with advanced prostate cancer. Taking into account the poorer prognosis in advanced disease, development of new therapeutic options as well we their adequate selection is of paramount importance. Enzalutamide is one of the second-generation androgen axis inhibitors, which has the ability to overcome resistance to androgen deprivation therapy by inhibiting the androgen-DNA signalling on several levels. Its efficacy and safety had been proven in numerous phase II and phase III clinical studies and it has been registered by regulatory authorities in the United States and European Union in the treatment of mCRPC, mCSPC and nmCRPC. In this article selected issues related to the treatment of prostate cancer are discussed, with particular emphasis on the role of enzalutamide (including its mechanism of action, indications, efficacy and safety).
Źródło:: OncoReview; 2022, 12, 2; 45-49
2450-6125
Pojawia się w:: OncoReview
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Informacja

Wyszukujesz frazę "hormonotherapy" wg kryterium: Temat

Źródło danych

Dostawca treści

Kolekcja

Rok wydania

Wydawca

Temat

Autor

Typ dokumentu

Język